
Aurion Biotech: Clinical-stage biotech firm pioneering advanced therapies to cure blindness.
Aurion Biotech is a clinical-stage biotech company focused on developing advanced therapies to cure blindness. Founded with the mission to restore vision and improve the quality of life for individuals suffering from ocular diseases, Aurion Biotech leverages cutting-edge technology and innovative research. The company's core product pipeline includes transformative treatments aimed at regenerating damaged eye tissues, particularly targeting conditions that lead to blindness. Their market focus is on providing groundbreaking solutions in the field of ophthalmology.
Notable affiliated individuals and investors include leading experts in biotechnology and ophthalmology, as well as prominent venture capital firms specializing in life sciences. Aurion Biotech has achieved significant milestones, including successful preclinical trials and securing substantial funding to advance their research. The company's impact is profound, offering hope to millions affected by vision impairment and positioning itself as a pioneer in the biotech industry dedicated to curing blindness.

Imagen Biotech

Qlaris Bio
qlaris.bio

Aureka Biotechnologies
aurekabio.com

Curie.Bio
curie.bio

Visiox
visioxpharma.com

Auron Therapeutics
aurontx.com

Orchid BioVentures

Revive Biotechnology
revivebiotech.com
Orion BioScience

Aurita
auritabio.com

Bionure
bionure.com

Skylark Bio
skylarkbio.com

Attralus
attralus.com

Regenerative Bio
regen-bio.us

Oculogenex
oculogenex.com
Companies similar to Aurion Biotech include Imagen Biotech, Qlaris Bio, Aureka Biotechnologies and Curie.Bio.
Aurion Biotech was founded in 2021.
Aurion Biotech's headquarters is located in Seattle, WA, US.
Aurion Biotech's most recent funding round was for $120M (USD) in April 2022.
As of Apr 12, 2022, Aurion Biotech has raised a total of $120M (USD).
Aurion Biotech has 55 employees as of Feb 5, 2024.